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Introduction
There has been a recent decline in the incidence of ST-
elevation myocardial infarction (STEMI) (1,2).  However, 
multivessel (MV) coronary artery disease (CAD) is 
frequently encountered (45–60%) in patients undergoing 
primary percutaneous coronary intervention (PCI) for 
STEMI (3-6). In contrast to stable lesions in stable 
CAD, non-culprit lesions in patients with acute coronary 
syndrome (ACS) tend to have more diffuse CAD and less-
calcified plagues (7,8). The plaques in ACS patients are also 
more vulnerable, with large amount of necrotic core (7) and 
thin-cap fibroatheromas, consistent with high-risk features. 
This could potentially lead to development of future 
major adverse cardiovascular events (9). The presence of 
MV-CAD is strongly associated with higher 30-day 
mortality, reduced myocardial reperfusion success, 
reinfarction, and occurrence of major adverse cardiac events 
(MACE) at 1-year compared with single vessel CAD (4-6). 
Despite higher morbidity and mortality in patients with 
STEMI and coexistent MV CAD, guidelines published 
by the American College of Cardiology/American Heart 
Association (ACC/AHA) in 2013 recommended against 
PCI on non-culprit lesions at the time of primary PCI in 
patients with STEMI who are hemodynamically stable (10). 
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The 2014 European Society of Cardiology/European 
Association of Cardio-Thoracic Surgery guidelines also 
similarly recommend systematic primary PCI of the 
culprit vessel and advocate for additional non-culprit vessel 
revascularization only in patients with cardiogenic shock, 
especially when the lesions are multiple, unstable, or with 
critical stenosis, and if persistent ischemia exists after PCI of 
the culprit lesion (11). However, only 25% of patients with 
cardiogenic shock and MV CAD receive MV PCI during 
STEMI (12).
The recommendations against PCI of non-culprit 
lesions were largely driven by results of nonrandomized 
observational studies with conflicting results. The 
rationale behind not recommending routine complete 
revascularization was increased in-hospital mortality, 
contrast-induced nephropathy (CIN), and MACEs 
associated with MV-PCI during the index procedure (13-17). 
Small randomized controlled trials (RCTs) reported 
potential safety and benefits of complete and staged 
revascularization in reducing long-term MACE (18,19). 
In multicenter randomized Hepacoat for Culprit or 
Multivessel Stenting for Acute Myocardial Infarction 
(HELP-AMI) study (19), with a total of 69 patients 
(17 patients in culprit-only PCI group and 52 patients 
in multivessel PCI group), the investigators found that 
MVPCI at the time of index procedure was not associated 
with increase in in-hospital adverse events and had similar 
overall healthcare cost as compared to culprit-only PCI (19). 
In the Primary Angioplasty in Patients Transferred From 
General Community Hospitals to Specialized PTCA Units 
With or Without Emergency Thrombolysis (PRAGUE-13) 
trial (20), the authors compared staged MV-PCI (n=106) 
with culprit-only PCI (n=108) in STEMI patients with 
MV-CAD. This study found no difference in the long 
term development of composite primary end-point of all-
cause mortality, non-fatal MI, and stroke between the two 
revascularization strategies (20).
The presence of MV-CAD often poses a therapeutic 
dilemma for interventional cardiologists as there are 
multiple options in patients with MV-CAD and insufficient 
data regarding benefit in reducing end-point such as 
mortality and MI. These options are culprit artery-only 
primary PCI, complete revascularization (MV-PCI) at the 
time of index procedure, or staged revascularization (primary 
PCI followed by ischemia or symptom guided PCI of the 
non-culprit lesion within days or weeks after primary PCI). 
In this review, we will discuss the recently published RCTs 
(Table S1) designed to investigate optimal revascularization 
strategy in managing STEMI patients with MV-CAD and 
their impact on current clinical practice and guidelines. 
RCTs (Table S1)
Politi et al. (18)
Out of a total of 263 consecutive patients with STEMI 
and MV-CAD, 214 patients were randomly assigned to 
culprit-only PCI (n=81), complete revascularization during 
the index procedure (n=65), and staged revascularization 
performed approximately two months after the index 
procedure (n=65) (18). Patients with cardiogenic shock at 
presentation (systolic blood pressure ≤90 mmHg despite 
drug therapy), left main coronary disease (≥50% diameter 
stenosis), previous coronary artery bypass graft (CABG) 
surgery, severe valvular heart disease and unsuccessful 
revascularization were excluded from the study. Patients 
were followed for a mean duration of 2.5±1.4 years (18).
The investigators found that culprit-only revascularization 
had a higher rate of at least one MACE (50%), compared 
to staged revascularization (20%) and immediate complete 
revascularization (23%) at a mean follow-up of 2.5 years 
(P<0.001) .  The s taged  and immediate  complete 
revascularization group had a 63% (P=0.003) and a 60% 
lower risk of MACE (P=0.002), respectively. This result 
was mainly driven by a lower incidence of in-hospital death, 
r e - P C I ,  a n d  r e h o s p i t a l i z a t i o n .  K a p l a n - M e i e r 
analysis showed a worse outcome in the culprit-only 
revascularization group (worse survival-free of MACE, 
survival-free of re-PCI), but no significant difference in 
outcomes between the staged and immediate complete 
revascularization groups. There were no significant 
differences in CIN incidence and length of hospital stay 
between the 3 study groups (18). This study suffered 
from a small sample size and utilization of unrestricted 
randomization instead of block randomization leading to 
imbalances in the treatment arms (25). It was also unclear 
whether patients in the culprit-only revascularization 
group had any non-invasive ischemia testing within 
2.5 years, which could qualify these patients for staged 
revascularization. This could potentially explain the higher 
incidence of repeat revascularization and re-hospitalization 
in the culprit-only revascularization group (26).
PRAMI (21)
In the Preventive Angioplasty in Acute Myocardial 
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Infarction (PRAMI) trial, a total of 465 patients were 
randomly assigned to culprit only revascularization 
(n=231) and complete revascularization during the index 
procedure (n=234) (21). Staged revascularization in the 
asymptomatic patients was discouraged. Once the infarct-
related artery was treated, the patients were included in the 
trial if they had a PCI-amenable ≥50% stenosis in one or 
more non-infarct-related coronary arteries. Patients who 
were in cardiogenic shock, unable to provide consent, had 
undergone previous CABG, had a non-infarct stenosis of 
50% or more in the left main stem or the ostia of both the 
left anterior descending and circumflex arteries, or if the 
only non-culprit stenosis was a chronic total occlusion were 
excluded. Patients were followed for a mean follow-up 
duration of 23 months (21).
This study reported a 65% reduction in the primary 
endpoint in the complete revascularization group compared 
to the culprit-only revascularization group. Complete 
revascularization group also had a significantly lower risk 
for repeat revascularization and composite of death from 
cardiac causes or non-fatal MI. The Kaplan-Meier analysis 
showed that the risk reduction benefit was apparent within 6 
months after the procedure (21). This study, however, failed 
to address the question whether similar benefit could be 
obtained when PCI was performed as a delayed procedure 
(staged revascularization) (27).
DANAMI-3 PRIMULTI (22)
In The Third Danish Study of Optimal Acute Treatment of 
Patients with STEMI: Primary PCI in Multivessel Disease 
(DANAMI-3 PRIMULTI), 627 patients were randomly 
allocated to complete revascularization (n=314) and culprit 
only revascularization (n=313) (22). After successful PCI of 
the culprit lesion, patients with an angiographic diameter 
stenosis of greater than 50% in one or more non-infarct 
related arteries were included in the trial. Patients were 
excluded if they were intolerant of contrast media or of 
relevant anticoagulant or antithrombotic drugs, unconscious 
or suffered from cardiogenic shock, stent thrombosis, met 
indication for CABG, or had an increased bleeding risk. 
Complete revascularization was performed in a staged 
manner 2 days after the index procedure during the index 
hospitalization, and was guided by fractional flow reserve 
(FFR), if appropriate. In non-culprit lesions with a greater 
than 50% diameter stenosis, FFR values were calculated 
(FFR ≤0.8 considered significant) (22).
One-third of patients allocated to the complete 
revascularization group did not receive PCI as they had 
FFR values >0.80. The investigators found that complete 
revascularization was associated with a 44% reduction in 
the incidence of the composite primary endpoint, which 
was largely driven by a 69% reduction of ischemia-driven 
revascularization of the non-infarct related arteries. There 
were no significant differences in the all-cause mortality and 
non-fatal reinfarction rates between the 2 groups. There 
were also no significant differences in cardiovascular death 
or non-fatal MI, although complete revascularization was 
significantly associated with a lower need for both urgent 
and non-urgent PCI of the lesions in the non-culprit 
arteries (22). This trial failed to show an impact on hard 
outcomes (such as death and MI due to lack of power). The 
optimal timing of non-infarct related artery PCI (index 
admission versus staged outpatient procedure) remains a 
debate (28,29).
CvLPRIT (23)
The Complete versus Lesion-only Primary PCI (CvLPRIT) 
trial randomized 296 STEMI patients and MVCAD to culprit-
only (n=146) and complete (n=150) revascularization (23). 
Exclusion criteria were an age <18 years, clear indication 
for, or contraindication to, MV primary PCI according to 
operator judgement, prior MI, patients with prior CABG, 
cardiogenic shock, ventricular septal rupture or moderate/
severe mitral regurgitation, chronic kidney disease, 
suspected or confirmed thrombosis of a previously stented 
artery, and when the only significant non-infarct-related 
lesion is a chronic total occlusion (23).
Complete revascularization was done either during 
the index procedure or the index hospitalization (staged 
revascularization). The primary endpoint of this study 
was MACE, which was a composite of all-cause mortality, 
recurrent MI,  heart  fa i lure,  and ischemic-driven 
revascularization by PCI or CABG within 12 months. 
This study reported a 55% reduction of MACE in the 
patients undergoing complete revascularization compared 
to the culprit-only revascularization. The occurrence 
of individual components of the primary endpoint was 
insignificantly lower in the complete revascularization 
group. Sixty-four percent of patients underwent complete 
revascularization during the index procedure, while the 
others had a staged revascularization. Patients receiving 
complete revascularization during the index procedure had 
a trend towards a reduced prevalence of MACE compared 
to staged revascularization. There were no differences in the 
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occurrence of adverse events, such as stroke, major bleeding 
(all non-CABG related), or CIN between the infarct-related 
revascularization and complete revascularization groups (23). 
The study was not powered to assess the individual 
components of the primary composite endpoint (30). The 
study did not include intravascular ultrasound or FFR for 
the non-infarct-related lesion characterization anatomically 
or physiologically, respectively. 
Compare-Acute Trial (24)
The Comparison Between FFR Guided Revascularization 
Versus Conventional Strategy in Acute STEMI Patients 
With MVD (COMPARE-ACUTE) Trial enrolled 885 
STEMI patients with non-infarct-related coronary stenosis of 
50% or more (24). Patients were randomly assigned in a ratio 
of 1:2 to FFR-guided complete revascularization (n=295) and 
culprit-only revascularization (n=590). Exclusion criteria 
were left main CAD, chronic total occlusion, severe stenosis 
with a Thrombolysis in Myocardial Infarction (TIMI) 
flow grade of 2 or less in the non-infarct-related coronary 
artery, a suboptimal result or complication after treatment 
of infarct-related artery, severe valve dysfunction, and Killip 
class III or IV. Complete revascularization was performed 
in lesions with FFR ≤0.80, preferably within 72 hours 
(complete PCI was performed during index procedure 
in 83.4 % patients). Primary end-point of the study was 
the composite of all-cause mortality, non-fatal MI, any 
revascularization, and cerebrovascular events (MACCE) at 
12 months (24).
As the FFR measurement was performed in both groups, 
this study showed that approximately half of the patients 
had one or more non-infarct-related artery lesions with an 
FFR of 0.80 or less. The investigators found that complete 
revascularization group had significantly lower rate of 
MACCE compared to culprit-only revascularization group 
which seems to be driven mainly by the decreased need for 
revascularization. The other components of primary end-
point (all-cause mortality, MI, and cerebrovascular event) 
did not differ statistically between both groups (24).
Al though th i s  s tudy  showed that  FFR-guided 
revascularization could be safely performed in acute setting 
of STEMI and cost-effective, it is questionable whether 
the result of trial can also be applied to much sicker patient 
populations. In addition, there is a potential bias as the 
angiographic result of culprit-only revascularization group 
was made known to patients and cardiologist, which could 
contribute to higher subsequent revascularization among 
that group (31).
Meta-analyses
Spencer et al. (32) in their systematic review, which included five 
RCTs [RCT by Politi et al. (18), HELP-AMI (19), PRAMI (21), 
DANAMI-3 PRIMULTI (22), and CvLPRIT (23)] enrolling 
1,606 patients, concluded that complete revascularization 
was associated with significant reduction in the risk of repeat 
revascularization, non-fatal MI, cardiovascular mortality 
compared to culprit-only revascularization. However, 
the investigators did not find any difference in the total 
mortality between the two groups (32). A separate meta-
analysis which recruited nine RCTs with total 2,176 patients, 
agreed that complete revascularization strategy was overall 
better in lowering risk of MACE, repeat revascularization, 
cardiovascular mortality, but found no difference in 
mortality or recurrent MI. The investigators also compared 
the three revascularization strategies (culprit-only, 
complete revascularization at index procedure, and complete 
revascularization as staged procedure) and showed that 
complete revascularization during index procedure seemed 
to be more superior than two other strategies (33). However, 
more recent meta-analysis, conducted by Fan et al. (34), 
concluded the opposite: complete revascularization as 
staged procedure deemed better than immediate complete 
revascularization or culprit-only revascularization in 
reducing all-cause mortality (34).
Numerous other meta-analyses have been conducted and 
published since the RCTs (Table 1). They have discordant 
results, which was largely driven by the inclusion of different 
variety of trials to conduct the meta-analyses and by the fact 
that none of the RCTs were adequately powered for the hard 
outcomes of death and MI. Overall, MV-PCI seems to be 
associated with lower risk of MACE, repeat revascularization, 
but with a similar risks of recurrent MI and mortality 
compared to culprit-only revascularization (32-44). 
Timing of revascularization
Timing of revascularization remains an area of intense 
controversy and debate. Wang et al. (43) performed a 
subgroup analysis in their meta-analysis, comparing 
outcomes in complete revascularization at the time of the 
index procedure (immediate complete revascularization) and 
staged revascularization with culprit-only revascularization. 
Immediate complete revascularization had a significantly 
lower incidence of MACE, all-cause death and/or MI, non-
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fatal MI, and repeat revascularization when compared to 
the culprit-only revascularization. Staged revascularization 
reduced only the incidence of MACE. This showed that 
immediate complete revascularization might be more 
superior compared to staged revascularization. This finding 
seems to be opposite of what was found in other meta-
analyses (40,44) and the few observational studies (45,46). 
Kornowski et al. (45) performed a post-hoc analysis of the 
Harmonizing Outcomes with Revascularization and Stents 
in Acute Myocardial Infarction (HORIZONS-AMI) trial. 
This was a RCT originally designed to compare bivalirudin 
versus heparin plus a glycoprotein IIb/IIIa inhibitor and 
paclitaxel-eluting stents versus bare-metal stents in patients 
undergoing primary PCI for STEMI. A total of 668 STEMI 
patients were identified to have undergone MV-PCI 
in the original trial. Two hundred and seventy-five patients 
underwent MV-PCI during the index procedure, whereas 
393 patients underwent staged revascularization (6–50 days 
after primary PCI). This study showed that MV-PCI during 
index procedure was associated with an increased all-cause 
mortality [hazard ratio (HR) 4.1, 95% CI: 1.93–8.86, 
P<0.0001] and cardiovascular mortality (HR 3.41, 95% CI: 
1.35–7.27, P=0.005) compared to the staged MV-PCI (45). 
Similarly, a meta-analysis by Tarantini et al. (40) revealed 
that staged revascularization was associated with short-and 
long-term survival compared with both immediate complete 
revascularization and culprit-only revascularization. In 
separate meta-analysis by Li et al. (44) which compared staged 
revascularization and immediate complete revascularization 
head-to-head, the former seemed to be a better strategy.
Iqbal et al. (46) performed an observational study which 
compared the 3 revascularization strategies (immediate 
complete revascularization, staged revascularization, and 
culprit-only revascularization) in 6,503 STEMI patients 
with MV-CAD. The primary outcome was all-cause 
mortality and repeat revascularization at 2 years. The 
investigators found that staged revascularization was 
associated with a lower mortality at 1 year and 2 years when 
compared with either immediate complete revascularization 
or culprit-only revascularization. This study also showed 
lower repeat revascularization rates at 30 days, 1 year, and 
2 years when compared with culprit-only revascularization. 
The authors concluded that staged PCI of the non-culprit 
vessel (if indicated) may yield better results, and MV-PCI at 
time of index procedure may be considered in patients with 
non-culprit LAD disease (46).
Of the RCTs discussed in detail above, Politi et al. (18) 
was the only trial that included both staged and immediate 
complete revascularization and analyzed them separately. 
PRAMI (21) was the only trial that specifically compared 
MV-PCI at time of index procedure to culprit-only 
revascularization. DANAMI-3 PRIMULTI (22) compared 
only staged revascularization to culprit only-revascularization. 
CvLPRIT (23) and Compare-Acute Trial (24) combined 
both immediate and staged revascularization (mentioned 
as complete revascularization) at time of data analysis. 
The variability on how the trials were conducted leads 
to uncertainty and confusion on when and how complete 
revascularization should be performed. This warrants a 
larger scale RCT to confirm the present findings, as well 
as to determine the impact of such intervention on hard 
endpoints such as mortality or MI.
A  l a rge ,  ongo ing ,  Comple te  v s .  Cu lpr i t -on ly 
Revascularization to Treat Multivessel Disease After Primary 
PCI for STEMI (COMPLETE) trial (ClinicalTrials.
gov. Identifier: NCT01740479) was designed to enroll 
3,900 STEMI patients with MV-CAD randomly assigning 
them to receive either staged revascularization or culprit-
only revascularization, on top of optimal medical therapy 
(including low dose aspirin and ticagrelor). This trial was 
started in December, 2012, and is estimated to be completed 
in December, 2018. The primary outcome of this study is a 
composite of cardiovascular death or new MI over a follow-up 
of approximately 4 years. The secondary outcome is a 
composite of cardiovascular death, new MI, ischemia-driven 
revascularization or hospitalization for unstable angina or 
heart failure. The results of this trial are expected to provide 
a better understanding of whether staged revascularization 
is better than culprit-only revascularization in STEMI 
patients with MV-CAD undergoing primary PCI. 
2015 ACC/AHA focused update and 2016 ACC/
AHA appropriate use criteria
The publication of larger scale RCTs has prompted 
ACC/AHA to change the recommendation for complete 
revascularization to class IIb in the recent 2015 ACC/
AHA/SCAI Focused Update on Primary Percutaneous 
Intervention for Patients with ST-Elevation Myocardial 
Infarction (47). These guidelines specifically mention 
that PCI of a non-infarct artery may be considered in 
selected patients with STEMI and MV-CAD who are 
hemodynamically stable, either at the time of primary PCI 
or as a planned staged procedure (47). 
The 2016 Appropriate Use Criteria for Coronary 
Revascularization in Patients with ACS also addressed the 
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issue on how to treat MV-CAD in STEMI patients (48). 
Multivessel revascularization at the time of the index 
procedure with PCI or CABG was deemed appropriate 
in patient with cardiogenic shock persisting after PCI of 
the presumed culprit artery. Whereas revascularization of 
non-culprit artery during initial hospitalization (as staged 
procedure) was considered appropriate in MV-CAD patients 
with spontaneous or easily provoked symptoms of myocardial 
ischemia, asymptomatic patients with findings of ischemia 
on non-invasive testing, and asymptomatic patients with an 
intermediate (50–70%) stenosis and a FFR ≤0.8 (48). 
Conclusions
In conclusion, it seems prudent to consider MV-PCI at the 
time of the index procedure in patients with cardiogenic 
shock, severe left ventricular dysfunction and hemodynamic 
instability. MV-PCI at the time of the index procedure can 
also be considered in patients with angiographically critical 
atherosclerotic plaques (high thrombus burden, ulcerated, 
TIMI flow <3, angiographic stenosis >95%) especially in 
the left anterior descending artery. MV-PCI at the index 
procedure may be considered in situations where it is difficult 
to determine the culprit lesion (for example coexistent 
left circumflex and right coronary artery critical lesions in 
patients with inferior wall ACS). In patients who are older, 
have chronic comorbid conditions such as diabetes or chronic 
kidney disease, a staged approach for non-culprit lesions 
may be preferred to prevent acute kidney injury. Timing of 
the staged procedure is debatable (same admission versus 
outpatient) and relies on the clinical scenario, ongoing 
symptoms and patient-physician preference after a risk-
benefit discussion. Noninvasive or invasive testing (FFR) may 
be considered in the non-acute staged setting, as appropriate. 
Until more data are available, an individualized approach 
should be adopted after careful evaluation of the lesion 
severity, hemodynamics, underlying comorbidities, vascular 
access, physician comfort, and cardiac catheterization 
laboratory ancillary staff availability (day versus night). 
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Table S1 RCTs of complete vs. culprit only revascularization
RCT Timing of study Study group
Total of 
patients
Number of patient in 
multivessel PCI
Number of patient 
in culprit-only PCI
Lesion criteria  
(% stenosis)
Timing for non-culprit lesion 
revascularization
Duration of  
follow up
Primary end-point Secondary end-point Study results
Politi et al. (18) Jan 2003–Dec 2007 Culprit only revascularization 
vs. staged revascularization 
vs. complete 
revascularization
214 Staged: 65 patients 
(30.4%); complete: 
65 patients (30.4%)
84 (39.2%) >70% of two or more coronary 
arteries or their major branches 
by visual estimation
During index procedure (30.4% 
of patients) or staged (30.4% of 
patients), staged procedure done 
56.8±12.9 days after the index 
procedure
2.5±1.4 years Major adverse cardiac event 
(cardiac or non-cardiac death, 
inhospital death, re-infarction,  
re-hospitalization for ACS and 
repeat coronary revascularization)
– 63% lower risk of MACE in staged 
revascularization group, 60% lower risk of 
MACE in complete revascularization group 
compared to culprit-only revascularization 
group, higher risk of repeat unplanned 
revascularization, rehospitalization 
and in-hospital death in culprit-only 
revascularization group
PRAMI (21) April 2008–January 
2013
Culprit only revascularization 
vs. complete 
revascularization
465 234 231 >50% stenosis During index procedure 23 months Composite of death from cardiac 
causes, non-fatal MI, refractory 
angina
Death from non-cardiac cause, repeat 
revascularization procedures (PCI or CABG)
65% reduction in primary outcome, no 
significant difference in death (either from 
cardiac or non-cardiac cause)
Danami-3 
PRIMULTI (22)
March 2011–Feb 2014 Culprit only revascularization 
vs. ffr-guided complete 
revascularization (staged)
627 314 313 >50% in one or more non-infarct 
related arteries
2 days after index procedure before 
discharge
27 (range  
12–44) months
Composite of all-cause mortality, 
reinfarction, or ischemia-driven 
revascularizations in non-infarct 
related arteries
Components of the primary end-point, 
occurrence of cardiac death, urgent and non-
urgent PCI of lesions in non-infarct related 
arteries
44% reduction in primary endpoint, largely 
driven by 69% reduction in all-cause 
mortality
CvLPRIT (23) May 2011–May 2014 Complete vs. culprit-only 
revascularization
296 150 146 >70% diameter stenosis in one 
plane or >50% in 2 planes
During index procedure or index 
admission
12 months MACE (all-cause mortality, 
recurrent MI, HF, ischemic-driven 
revascularization by PCI/CABG)
Cardiovascular death, individual component of 
the primary endpoint, and the safety endpoints 
of stroke, major bleeding, and CIN
55% lower risk of MACE in complete 
revascularization group
Compare-
Acute Trial (24)
July 2011–October 
2015
Culprit-only revascularization 
vs. ffr-guided complete 
revascularization
885 295 590 >50% plus history of angina or 
evidence of ischemia; or >70% 
on angiography; with FFR ≤0.80
During index hospitalization (83.4% 
of patients had complete PCI during 
index procedure)
36 months Composite of all-cause 
mortality, non-fatal MI, 
any revascularization, and 
cerebrovascular events at 12 
months
Primary end-point at 24 and 36 months; each 
components of primary end-point; composite 
of all-cause mortality and MI; composite of 
cardiac death, MI, any revascularization, stroke, 
and major bleeding; composite of heart failure 
hospitalization and unstable angina pectoris; 
stent thrombosis; treatment cost; bleeding at 
48 hours and 12 months
65% lower risk of primary end-point, 
largely drive by 68% reduction in 
revascularization
ACS, acute coronary syndrome; RCT, randomized controlled trial; MACE, major adverse cardiac events; MI, myocardial infarction; CV, cardiovascular; PCI, percutaneous coronary intervention; HF, heart failure; CIN, contrast-induced nephropathy; CABG, coronary artery bypass grafting.
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